
OpenEvidence makes an AI helper for diagnosis, aiming to answer clinical questions faster
The fast-growing startup is building AI support for doctors, with real implications for how evidence gets found.

Curating from trusted global sources…
Curated from trusted global sources, refined into briefing-grade analysis with executive summaries, insights, and bullet-point takeaways.

The fast-growing startup is building AI support for doctors, with real implications for how evidence gets found.

Hong Kong’s benchmark tech index welcomed MiniMax and Zhipu Monday, in a move that could pull in passive AI money.

Behind the hype, Chinese makers cut prices, but key “robot” features are still missing.

A battery that goes from 10% to 98% in under six-and-a-half minutes, showcased in Beijing, may force competitors to reprice.

Acadian’s Owen Lamont points to a bubble signal in forecast earnings, as rate-fears and weak guidance trigger a sell-off.

A new memory-chip agreement is not enough to stop South Korean stocks sliding as the AI trade cools.

Hang Seng falls while Hang Seng Tech, CSI 300, and Star Market retreat on bets the Fed hikes after a blowout jobs report.

After winning both races, Golden Tempo secures the argument for best 3-year-old Thoroughbred.

This week’s new private offerings show regulatory tightening has not stopped big firms from betting on Hong Kong high-net-worth growth.

CNBC reports more Hong Kong IPOs disappoint post-listing, raising tough questions about pricing, momentum, and investor protection.

The same AI players are selling each other shovels, and the retention math is about to hurt.

Americans keep picking Wegovy as a top weight-loss option despite new GLP-1 competition, shaping what buyers and investors reward.